A compound having the following structure (I): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: X is -S(O) n - or -C(R 8 R 9 )-; R 1 is H, hydroxyl or -OC(=O)R 13 ; R 2 is hydroxyl or -OC(=O)R 13 ; R 3 is: i) an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocyclyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom, wherein the optional substituent is one or more R 6 ; ii) pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, or tetrazine; or iii) -NH 2 , -NHC(=O)R 13 , -N(C(=O)R 13 ) 2 , -NHS(O) n R 5 , -N(C(=O)R 13 )(S(O) n R 5 ), - N(C 1 -C 6 alkyl)(S(O) n R 5 ) or -S(O) n R 5 ; R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ; R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl; R 8 and R 9 are each independently H or C 1 -C 6 alkyl; R 11a , R 11b , R 11c and R 11d are each independently H, methyl, F, Cl, Br, I, or 123 I; R 13 is C 1 -C 6 alkyl; and n is 0, 1, or 2; wherein at least two of R 11a , R 11b , R 11c and R 11d are methyl, F, Cl, Br, I, or 123 I. X is -S(O) n - or -C(R 8 R 9 )-; R 1 is H, hydroxyl or -OC(=O)R 13 ; R 2 is hydroxyl or -OC(=O)R 13 ; R 3 is: i) an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocyclyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom, wherein the optional substituent is one or more R 6 ; ii) pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, or tetrazine; or iii) -NH 2 , -NHC(=O)R 13 , -N(C(=O)R 13 ) 2 , -NHS(O) n R 5 , -N(C(=O)R 13 )(S(O) n R 5 ), - N(C 1 -C 6 alkyl)(S(O) n R 5 ) or -S(O) n R 5 ; i) an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocyclyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom, wherein the optional substituent is one or more R 6 ; ii) pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, or tetrazine; or iii) -NH 2 , -NHC(=O)R 13 , -N(C(=O)R 13 ) 2 , -NHS(O) n R 5 , -N(C(=O)R 13 )(S(O) n R 5 ), - N(C 1 -C 6 alkyl)(S(O) n R 5 ) or -S(O) n R 5 ; R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ; R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl; R 8 and R 9 are each independently H or C 1 -C 6 alkyl; R 11a , R 11b , R 11c and R 11d are each independently H, methyl, F, Cl, Br, I, or 123 I; R 13 is C 1 -C 6 alkyl; and n is 0, 1, or 2; <EOS>